The Kidney Health Initiative (KHI) is seeking input from patients and their families on new treatment options to reduce the burden of kidney disease. Through a series of webinars and conference calls, participants can share their perspectives and preferences for future therapies for kidney disease, the 9th leading cause of death in the United States. These patient preference forums are the latest project from KHI, a public-private partnership between the American Society of Nephrology and the U.S. Food and Drug Administration to advance kidney health issues.
Participants will learn about the FDA’s role in drug and device development, and how the agency will use their ideas to help guide new treatments and products that meet patient needs. The webinars will take place on:
Tuesday, April 14 5:00 p.m. – 6:00 p.m. EDT
Wednesday, April 22 8:00 p.m. – 9:00 p.m. EDT
Friday, April 24 12:00 p.m. – 1:00 p.m. EDT
To participate, interested individuals must register by completing a brief survey no later than a day before their preferred time and date. The survey is available at http://asn.kdny.info/L8Q6f.
Participants may be asked to attend a future workshop to share their ideas directly with the FDA, scientists, doctors, nurses and technicians. More information on the workshop, including the opportunity for travel support, will be provided at a later date.
Established in 2012, KHI’s mission is to advance scientific understanding of the kidney health and patient safety implications of new and existing medical products and to foster development of new therapies. More than 70 KHI member organizations and companies represent all major stakeholders in the field of kidney disease, including patient and health professional organizations, pharmaceutical companies, device manufacturers, dialysis providers, research institutions, and federal agencies.